A Laudisio, S Giovannini1, P Finamore, A Gemma, R Bernabei, R A Incalzi, G Zuccalà. 1. Silvia Giovannini, MD, PhD, Department of Geriatrics, Neurosciences, and Orthopaedics, Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore - Roma, Italy, silvia_giovannini@yahoo.it.
Abstract
BACKGROUND: Improved ability to treat chronic diseases have increased the interest in measuring health-related quality of life (HRQoL) in older adults. Hypertension and heart failure have been associated with decreased HRQoL. HYPOTHESIS: The aim of this study was to assess the association between health-related quality of life and use of angiotensin converting enzyme inhibitors in unselected community-dwelling elderly. METHODS: We analyzed data of all 387 subjects aged 75+ living in a rural Italian town, without exclusion criteria. HRQoL was assessed using the Health Utility Index Mark 3, which allows formal cost-effectiveness calculations. The association of the HRQoL score with use of ACE-I was analyzed by multivariable linear and logistic regression. RESULTS: The median HUI3 score was 0.31, and 186 participants (48%) reported a score above the median value. Use of ACE-I was reported by 34 (9%) participants, and confirmed by general practitioners. Use of these agents was associated with significantly better HRQoL (B=.16, 95% CI=.02 - .30; P=.025). Also, use of ACE-I was associated with increased probability of better HRQoL in logistic regression (OR=2.83; 95% CI=1.03 - 7.78; P=.044) after adjusting. No associations were found between the HRQoL score and use of calcium antagonists or beta-blockers. CONCLUSIONS: Use of ACE-I, but not of other antihypertensives, is associated with better HRQoL among community-dwelling older adults. ACE-inhibitors might therefore present with the best cost-effectiveness ratio for the treatment of older populations.
BACKGROUND: Improved ability to treat chronic diseases have increased the interest in measuring health-related quality of life (HRQoL) in older adults. Hypertension and heart failure have been associated with decreased HRQoL. HYPOTHESIS: The aim of this study was to assess the association between health-related quality of life and use of angiotensin converting enzyme inhibitors in unselected community-dwelling elderly. METHODS: We analyzed data of all 387 subjects aged 75+ living in a rural Italian town, without exclusion criteria. HRQoL was assessed using the Health Utility Index Mark 3, which allows formal cost-effectiveness calculations. The association of the HRQoL score with use of ACE-I was analyzed by multivariable linear and logistic regression. RESULTS: The median HUI3 score was 0.31, and 186 participants (48%) reported a score above the median value. Use of ACE-I was reported by 34 (9%) participants, and confirmed by general practitioners. Use of these agents was associated with significantly better HRQoL (B=.16, 95% CI=.02 - .30; P=.025). Also, use of ACE-I was associated with increased probability of better HRQoL in logistic regression (OR=2.83; 95% CI=1.03 - 7.78; P=.044) after adjusting. No associations were found between the HRQoL score and use of calcium antagonists or beta-blockers. CONCLUSIONS: Use of ACE-I, but not of other antihypertensives, is associated with better HRQoL among community-dwelling older adults. ACE-inhibitors might therefore present with the best cost-effectiveness ratio for the treatment of older populations.
Entities:
Keywords:
ACE-inhibitors; elderly; quality of life
Authors: A Degl'Innocenti; D Elmfeldt; A Hofman; H Lithell; B Olofsson; I Skoog; P Trenkwalder; A Zanchetti; I Wiklund Journal: J Hum Hypertens Date: 2004-04 Impact factor: 3.012
Authors: John S Rumsfeld; Karen P Alexander; David C Goff; Michelle M Graham; P Michael Ho; Frederick A Masoudi; Debra K Moser; Véronique L Roger; Mark S Slaughter; Kim G Smolderen; John A Spertus; Mark D Sullivan; Diane Treat-Jacobson; Julie J Zerwic Journal: Circulation Date: 2013-05-06 Impact factor: 29.690
Authors: S H Croog; S Levine; M A Testa; B Brown; C J Bulpitt; C D Jenkins; G L Klerman; G H Williams Journal: N Engl J Med Date: 1986-06-26 Impact factor: 91.245
Authors: Angela H Boal; Daniel J Smith; Linsay McCallum; Scott Muir; Rhian M Touyz; Anna F Dominiczak; Sandosh Padmanabhan Journal: Hypertension Date: 2016-10-10 Impact factor: 10.190
Authors: Nina Rosa Neuendorff; Kah Poh Loh; Alice S Mims; Konstantinos Christofyllakis; Wee-Kheng Soo; Bediha Bölükbasi; Carlos Oñoro-Algar; William G Hundley; Heidi D Klepin Journal: Blood Adv Date: 2020-02-25